These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35842685)

  • 1. Real-world safety of ulinastatin: a post-marketing surveillance of 11,252 patients in China.
    Li J; Li M; Li L; Ma L; Cao A; Wen A; Chen W; Li L; Liang Y; Deng J
    BMC Pharmacol Toxicol; 2022 Jul; 23(1):51. PubMed ID: 35842685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of the Xuesaitong injection in China: results from a large-scale multicentre post-marketing surveillance study in a real-world setting.
    He Y; Gao XM; Li L; Liu XG; Liu W; Hong XJ; Huang BH; Yang HL; Xue MH; Wu XJ; Liu JF
    Curr Med Res Opin; 2020 Dec; 36(12):1947-1953. PubMed ID: 33016133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-marketing safety surveillance and re-evaluation of Xueshuantong injection.
    Li C; Xu T; Zhou P; Zhang J; Guan G; Zhang H; Ling X; Li W; Meng F; Liu G; Lv L; Yuan J; Li X; Zhu M
    BMC Complement Altern Med; 2018 Oct; 18(1):277. PubMed ID: 30326892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Technical specifications for intensive hospital safety monitoring of post-marketing Chinese medicine (draft version for comments)].
    Xie YM; Liao X; Zhao YB; Li MQ; Zhang YL; Ma R; Xian SX; Liu J; Li SY; Wen ZH; Yang ZQ; Zou JD; Sun HS; He Y; Li XL; Jiang JJ; Wang ZF; Li YY; Wang LX; Chang YP; Yang W; Zhang W
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2919-24. PubMed ID: 24471304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-Marketing Safety Surveillance of the Salvia Miltiorrhiza Depside Salt for Infusion: A Real World Study.
    Yan YY; Yang YH; Wang WW; Pan YT; Zhan SY; Sun MY; Zhang H; Zhai SD
    PLoS One; 2017; 12(1):e0170182. PubMed ID: 28125608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Post-marketing surveillance of
    Li XX; Zhuo L; Yang YH; Zhan SY; Zhai SD
    Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Feb; 38(2):248-252. PubMed ID: 28231676
    [No Abstract]   [Full Text] [Related]  

  • 7. [Post-marketing safety surveillance of Diemailing Kudiezi injection: real world study in 30 233 cases].
    Liao X; Yu DD; Xie YM; Zhang YL; He Y; Zhang Y; Liu Y; Yi DH; Wang YY
    Zhongguo Zhong Yao Za Zhi; 2017 Aug; 42(15):2857-2863. PubMed ID: 29139248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of adverse drug reactions in a vemurafenib early post-marketing phase vigilance study in Japan.
    Uhara H; Kiyohara Y; Tsuda A; Takata M; Yamazaki N
    Clin Transl Oncol; 2018 Feb; 20(2):169-175. PubMed ID: 28674996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-marketing safety monitoring of shenqifuzheng injection: a solution made of dangshen (Radix Codonopsis) and huangqi (Radix Astragali Mongolici).
    Ai Q; Zhang W; Xie Y; Huang W; Liang H; Cao H
    J Tradit Chin Med; 2014 Aug; 34(4):498-503. PubMed ID: 25185371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse drug events in an intensive care unit of a university hospital.
    Reis AM; Cassiani SH
    Eur J Clin Pharmacol; 2011 Jun; 67(6):625-32. PubMed ID: 21246350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preventing Adverse Drug Reactions After Hospital Discharge (PADR-AD): Protocol for a randomised-controlled trial in older people.
    Cousins J; Parameswaran Nair N; Curtain C; Bereznicki B; Wilson K; Adamczewski B; Barratt A; Webber L; Simpson T; McKenzie D; Connolly M; Bereznicki L
    Res Social Adm Pharm; 2022 Aug; 18(8):3284-3289. PubMed ID: 34593344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-marketing safety surveillance and reevaluation of Motherwort injection: A clinical study of 10 094 cases.
    Cao Shan DOSOGC; Zhang W; Zhao Z; Heng M; Bu H; Wang H; Liu X; Wang Z; Cai Y; Ma Y; Cui Shihong DOO; Deng J; Yang Y; Ding G; Ding Y; Dong L; Duan Z; Fan L; Fan Y; Fu F; He J; Ji S; Jin L; Li H; Li H; Liao T; Lu W; Luo X; Lü Z; Ma F; Ma D; Shi T; Sun J; Teng H; Wang J; Wang R; Wang Y; Wang Z; Xi J; Xu M; Xu Z; Yan Q; Zhang G; Yang C; Yin J; Yu J; Yuan W; Zhang M; Zhao R; Zhong Y; Zhou J
    J Tradit Chin Med; 2018 Aug; 38(4):625-635. PubMed ID: 32186089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse drug event reporting in intensive care units: a survey of current practices.
    Kane-Gill SL; Devlin JW
    Ann Pharmacother; 2006; 40(7-8):1267-73. PubMed ID: 16849619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse drug reactions amongst adult patients admitted in Lagos State University Teaching Hospital Lagos, Nigeria.
    Aderemi-Williams RI; Awodele O; Boyle CA
    Curr Drug Saf; 2015; 10(2):136-44. PubMed ID: 24909574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Knowledge creation about ADRs--turning the perspective from the rear mirror to the projector?
    Aagaard L; Soendergaard B; Stenver DI; Hansen EH
    Br J Clin Pharmacol; 2008 Mar; 65(3):364-76. PubMed ID: 17961195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of adverse drug events and adverse drug reactions in hospital among older patients with dementia: A systematic review.
    Sakiris MA; Sawan M; Hilmer SN; Awadalla R; Gnjidic D
    Br J Clin Pharmacol; 2021 Feb; 87(2):375-385. PubMed ID: 32520427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ["Re-evaluation upon suspected event" is an approach for post-marketing clinical study: lessons from adverse drug events related to Bupleuri Radix preparations].
    Wu SX; Sun HF; Yang XH; Long HZ; Ye ZG; Ji SL; Zhang L
    Zhongguo Zhong Yao Za Zhi; 2014 Aug; 39(15):2983-8. PubMed ID: 25423845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of adverse drug events on morbidity and mortality in intensive care units: the JADE study.
    Ohta Y; Sakuma M; Koike K; Bates DW; Morimoto T
    Int J Qual Health Care; 2014 Dec; 26(6):573-8. PubMed ID: 25192926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety Profile of Oxaliplatin in 3,687 Patients With Cancer in China: A Post-Marketing Surveillance Study.
    Yu Z; Huang R; Zhao L; Wang X; Shangguan X; Li W; Li M; Yin X; Zhang C; Liu D
    Front Oncol; 2021; 11():757196. PubMed ID: 34745993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-marketing surveillance study with iodixanol in 20 185 Chinese patients from routine clinical practices.
    Zhang BC; Hou L; Lv B; Xu YW
    Br J Radiol; 2014 Feb; 87(1034):20130325. PubMed ID: 24357597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.